MicroCME: JAK Inhibitors
![]()
Price: FREE to members; $20 non-members
Length: 10 minutes
This microlearning, presented by Dr. Clinton Dunn, discusses how IL‑2–driven Tregs and JAK inhibitors help rein in atopic immune overactivity.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Practicing allergists
Allied health professionals
Primary Care Providers
Fellows-in-Training
Learning Objectives
By participating in this course, learners should be able to describe how T-regulatory cells are induced by IL-2 to suppress "undesired" immune pathways, and how enhancing the natural function of these cells could be a highly-effective way to dampen the exaggerated responses seen in atopic disease.
Planners and Reviewers
Brianne Nicole Navetta-Modrov, MD, FACAAI
Nothing to Disclose
Deepa Patadia, MD
Nothing to Disclose
Deepti Vellaichamy Manian, MD
Nothing to Disclose
Farah Nawaz Khan, MD, FACAAI
Doximity: stocks/stock options
Joel S. Klein, MD, FACAAI
Nothing to Disclose
Karen M. Anstey, MD
Nothing to Disclose
Tammy Peng, MD
Nothing to Disclose
Mary Brandt Hudelson, MD, FACAAI
Nothing to Disclose
Mechelle Miller Vazquez, MD
Nothing to Disclose
Available Credit
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Attendance
- 0.25 CBRN

Facebook
X
LinkedIn
Forward